Trafalgar International, Inc. (GCAN): Total Liabilities
$742.5K
As of 2025-12-31
$12.2K
As of 2026-06-30
-3.5%
3-year compound annual growth
+10.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $742.5K | -17.3% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $898.1K | +7.7% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $833.5K | +1.0% | 2025-05-05, Balance as of period end |
| 2022-12-31 | $825.3K | -4.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $862.0K | +87.4% | 2023-04-13, Balance as of period end |
| 2020-12-31 | $459.9K | -71.2% | 2022-04-12, Balance as of period end |
| 2019-12-31 | $1.60M | +124.2% | 2021-03-26, Balance as of period end |
| 2018-12-31 | $713.4K | +82.2% | 2020-04-14, Balance as of period end |
| 2017-12-31 | $391.6K | +260.0% | 2018-04-26, Balance as of period end |
| 2016-12-31 | $108.8K | n/a | 2018-04-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Trafalgar International, Inc. (GCAN) | 2025-12-31 | $742.5K | -17.3% |
| Nika Pharmaceuticals, Inc (NIKA) | 2025-12-31 | $318.6K | +33.2% |
| One World Products, Inc. (OWPC) | 2024-12-31 | $5.26M | +35.7% |
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $10.39M | +10.8% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $2.36M | +36.5% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $6.56M | +21.9% |
| Cell Source, Inc. (CLCS) | 2024-12-31 | $18.82M | +19.1% |
| ZyVersa Therapeutics, Inc. (ZVSA) | 2025-12-31 | $12.73M | +5.4% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $2.45M | +17.9% |
Compare GCAN, NIKA, OWPC, SKVI side by side · Screen every company in Pharmaceutical Preparations ↗